Centers for Advanced Research

APDA Centers for Advanced Research received $800,000 in funding in 2016.

The Centers support large research programs which include: research trainees; fellowship programs; early stage discovery programs and later stage clinical translation. These Centers facilitate research which is at the forefront investigations in the causes, treatments and ultimately finding the cure(s) for Parkinson’s disease.

University of Alabama at Birmingham, School of Medicine

David G. Standaert, MD, PhD, Director

APDA funding supports:

  • Inflammation in PD
  • 5,054 patient visits per year
  • Deep Brain Stimulation (DBS) Program
  • 24 peer-reviewed manuscripts

UCLA David Geffen School of Medicine

Marie-Francoise Chesselet, MD, Ph.D,Director

APDA funding supports:

  • Epidemiological studies in humans
  • Genetic & molecular studies in model organisms
  • Preclinical assessment of investigational therapies
  • Approximately 1,000 patient visits per year

Emory University School of Medicine

Mahlon R. DeLong, MD, Director

APDA funding supports:

  • Functional surgery
  • Research trainees
  • Two day intensive evaluation of Parkinson’s Disease patients
  • Approximately 10,000 total patients seen each year

Boston University School of Medicine

Marie Hélène Saint-Hilaire, MD, FRCP (C), Director

APDA funding supports:

  • Observational study of Social Self-Management in PD
  • Study of Tai Chi in PD
  • Active clinical trials program- Approximately 3,500 Parkinson’s Disease patient visits this year

Washington University School of Medicine

Joel S. Perlmutter, MD, Director

APDA funding supports:

  • Provided pilot data for six currently funded NIH RO1 grants
  • Biomarkers for Parkinson’s Disease & cognitive impairment occurrence
  • Exercise, emphasizing gait and balance
  • More than 4,000 Parkinson’s Disease patient visits

Rutgers-Robert Wood Johnson Medical School

Lawrence I. Golbe, MD, Director

APDA funding supports:

  • Neuroprotective activity of a non-caffeine component of coffee
  • The role of TG2 in the pathologic aggregation of alpha-synuclein
  • L-dopa induced dyskinesia Atypical parkinsonism, progressive supranuclear palsy
  • 999 patient visits per year

University of Pittsburgh Medical Center

J. Timothy Greenamyre, MD, PhD, Director

APDA funding supports:

  • Fellowship program in movement disorders
  • Intraoperative MRI guided DBS offered
  • Non-motor symptoms study
  • Therapeutic alpha-synuclein knockdown study
  • 1,000 patient visits per year

University of Virginia Health System

Madaline B. Harrison, MD, Director

APDA funding supports:

  • MR guided focused ultrasound projects
  • Genetics and characterization of neuropsychiatric disorders in Parkinson’s Disease
  • Heritability of motor and non-motor symptoms in PD
  • Approximately 857 patient visits per year